Peptide-Coupled siRNA for Lower Immunostimulatory Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy methods using nucleic acids often induce non-specific immunostimulatory reactions, leading to side effects such as redness, inflammation, and flu-like symptoms due to toll-like receptor activation, which current chemical modifications of the sugar-phosphate backbone fail to adequately address.
Innovation Solution
Coupling a peptide to a nucleic acid molecule, particularly siRNA, to reduce immunostimulatory reactions by binding at the antisense strand, thereby inhibiting the activation of genes associated with TLR reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are used in gene therapy to achieve targeted cellular influence, then therapeutic effectiveness is improved, but immunostimulatory side effects increase
Solution Approach 1:
A peptide is introduced as an intermediary component that binds to the nucleic acid molecule. This peptide acts as a mediator between the nucleic acid and the cellular machinery, specifically blocking the interaction between the nucleic acid and Toll-like receptors (TLRs). The peptide serves as a protective intermediary that allows the nucleic acid to maintain its therapeutic function while preventing harmful immunostimulatory responses.
Solution Approach 2:
The peptide is designed to preemptively block TLR activation before the nucleic acid can trigger immunostimulatory reactions. By pre-positioning the peptide on the nucleic acid molecule, the system prevents the harmful interaction between the nucleic acid and TLRs from occurring in the first place, rather than attempting to counteract the reaction after it begins.
2Stability of the object's composition
If chemical modifications of the sugar-phosphate backbone are applied to protect against nucleases, then stability is improved, but immunostimulatory reactions are not sufficiently reduced
Solution Approach 1:
The invention creates a composite structure by covalently combining a peptide with a nucleic acid molecule. This composite peptide-nucleic acid conjugate maintains the stability benefits of chemically modified nucleic acids while adding the immunomodulatory function of the peptide. The composite structure allows both components to contribute their specific functions: the nucleic acid provides therapeutic activity and the peptide provides TLR blocking.
3Productivity
If liposomal delivery strategies are used to enhance nucleic acid delivery, then delivery efficiency is improved, but extracellular TLR activation increases leading to enhanced systemic effects
Solution Approach 1:
The peptide component serves multiple functions simultaneously: it acts as a delivery facilitator to enhance cellular uptake, a protective element to prevent nuclease degradation, and an immunomodulatory agent to block TLR activation. This multi-functionality allows the single peptide addition to address multiple challenges in the delivery system without requiring separate components for each function.
Data Source
AI summary
What is described is a peptide for use in the reduction of side-effects in form of immunostimulatory reactions/effects which occur with gene therapy, wherein the peptide is coupled to a nucleic acid molecule used in gene therapy. Furthermore, such a peptide is described for use in the reduction of side-effects in form of immunostimulatory reactions/effects which occur with gene therapy, wherein the peptide is coupled to a nucleic acid molecule used in gene therapy, wherein the immunostimulatory reactions/effects are induced by activation of IFIT1/2, IRF9, TLR3, TLR7, TLR8 or PKR.